These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 19458375)

  • 1. Cytochrome P-450 polymorphisms and response to clopidogrel.
    Taubert D; Bouman HJ; van Werkum JW
    N Engl J Med; 2009 May; 360(21):2249-50; author reply 2251. PubMed ID: 19458375
    [No Abstract]   [Full Text] [Related]  

  • 2. Cytochrome P450 2C19 polymorphism and clopidogrel after MI.
    Miao J; Liu R; Li Z
    Lancet; 2009 Apr; 373(9670):1171-2; author reply 1172-3. PubMed ID: 19345824
    [No Abstract]   [Full Text] [Related]  

  • 3. Platelet inhibitors: update on clopidogrel (Plavix) and the recently approved prasugrel (Effient).
    Wynn RL
    Gen Dent; 2010; 58(1):7-9. PubMed ID: 20129886
    [No Abstract]   [Full Text] [Related]  

  • 4. In brief: poor metabolizers of clopidogrel (plavix).
    Med Lett Drugs Ther; 2010 May; 52(1337):33. PubMed ID: 20431520
    [No Abstract]   [Full Text] [Related]  

  • 5. Genotyping, clopidogrel metabolism, and the search for the therapeutic window of thienopyridines.
    Steinhubl SR
    Circulation; 2010 Feb; 121(4):481-3. PubMed ID: 20083686
    [No Abstract]   [Full Text] [Related]  

  • 6. Cytochrome P450 2C19 polymorphism and clopidogrel after MI.
    Ramaraj R
    Lancet; 2009 Apr; 373(9670):1172; author reply 1172-3. PubMed ID: 19345827
    [No Abstract]   [Full Text] [Related]  

  • 7. Omeprazole: a possible new candidate influencing the antiplatelet effect of clopidogrel.
    Gurbel PA; Lau WC; Tantry US
    J Am Coll Cardiol; 2008 Jan; 51(3):261-3. PubMed ID: 18206733
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.
    Scott SA; Sangkuhl K; Gardner EE; Stein CM; Hulot JS; Johnson JA; Roden DM; Klein TE; Shuldiner AR;
    Clin Pharmacol Ther; 2011 Aug; 90(2):328-32. PubMed ID: 21716271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics and clopidogrel response in patients undergoing percutaneous coronary interventions.
    Beitelshees AL; Horenstein RB; Vesely MR; Mehra MR; Shuldiner AR
    Clin Pharmacol Ther; 2011 Mar; 89(3):455-9. PubMed ID: 21270785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytochrome P450 2C19 polymorphism and clopidogrel after MI.
    Bhattacharyya S; Rakhit R
    Lancet; 2009 Apr; 373(9670):1171; author reply 1172-3. PubMed ID: 19345825
    [No Abstract]   [Full Text] [Related]  

  • 11. Current status of clopidogrel pharmacogenomics.
    Giusti B; Gori AM; Marcucci R; Abbate R
    Pharmacogenomics; 2012 Nov; 13(15):1671-4. PubMed ID: 23171330
    [No Abstract]   [Full Text] [Related]  

  • 12. Clopidogrel, genetics, and drug responsiveness.
    Freedman JE; Hylek EM
    N Engl J Med; 2009 Jan; 360(4):411-3. PubMed ID: 19164193
    [No Abstract]   [Full Text] [Related]  

  • 13. Cytochrome p-450 polymorphisms and response to clopidogrel.
    Mega JL; Close SL; Wiviott SD; Shen L; Hockett RD; Brandt JT; Walker JR; Antman EM; Macias W; Braunwald E; Sabatine MS
    N Engl J Med; 2009 Jan; 360(4):354-62. PubMed ID: 19106084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytochrome P-450 polymorphisms and response to clopidogrel.
    Miao J; Liu R; Li Z
    N Engl J Med; 2009 May; 360(21):2250-1. PubMed ID: 19469033
    [No Abstract]   [Full Text] [Related]  

  • 15. Clopidogrel in acute coronary syndrome: to genotype or not?
    Storey RF
    Lancet; 2009 Jan; 373(9660):276-8. PubMed ID: 19108882
    [No Abstract]   [Full Text] [Related]  

  • 16. Putting genomics into practice.
    Holmes MV; Casas JP; Hingorani AD
    BMJ; 2011 Aug; 343():d4953. PubMed ID: 21816737
    [No Abstract]   [Full Text] [Related]  

  • 17. [Informativeness of genetic factors for optimization of personalized therapy with clopidogrel].
    Knauér NIu; Lifshits GI; Voronina EN; Koleda NV; Gus'kova EV
    Kardiologiia; 2013; 53(8):72-5. PubMed ID: 24088005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clopidogrel pharmacogenetics: metabolism and drug interactions.
    Close SL
    Drug Metabol Drug Interact; 2011; 26(2):45-51. PubMed ID: 21819266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
    Sibbing D; Koch W; Gebhard D; Schuster T; Braun S; Stegherr J; Morath T; Schömig A; von Beckerath N; Kastrati A
    Circulation; 2010 Feb; 121(4):512-8. PubMed ID: 20083681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans.
    Farid NA; Kurihara A; Wrighton SA
    J Clin Pharmacol; 2010 Feb; 50(2):126-42. PubMed ID: 19948947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.